Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | EYA2 | O00167 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590779 | 0.90 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| SCHEMBL5551298 | 0.88 | TDP1 (0.68) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL8463064 | 0.77 | TDP1 (0.73) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL9771757 | 0.77 | TDP1 (0.73) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL670055 | 0.77 | TDP1 (0.73) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL20409 | 0.77 | TDP1 (0.73) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL15532203 | 0.77 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| SCHEMBL6563296 | 0.76 | — | — | |
| SCHEMBL10733820 | 0.74 | TDP1 (0.52) | TDP1EYA2APPACEBLM | |
| SCHEMBL2467758 | 0.74 | TDP1 (0.52) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104379-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
| EP-0822943-B9 | INULIN DERIVATIVES | COOPERATIE COSUN U A (NL) | 2007-02-28 | — | — | EP | disclosed |
| EP-0822943-B2 | INULIN DERIVATIVES | COOPERATIE COSUN U A (NL) | 2006-07-26 | — | — | EP | disclosed |
| EP-0822943-B1 | INULIN DERIVATIVES | COOPERATIE COSUN U A (NL) | 1999-07-14 | — | — | EP | disclosed |
| EP-0822943-A1 | INULIN DERIVATIVES | Coöperatie Cosun U.A. (NL) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996034017-A1 | INULIN DERIVATIVES | COÖPERATIE SUIKER UNIE U.A. (NL) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | TDP1 4770/4885EYA2 2451/4885APP 1563/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | TDP1 4770/4885EYA2 2451/4885APP 1563/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | TDP1 4770/4885EYA2 2451/4885APP 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.